| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9416361 | SAREPTA THERAPS INC | Splice-region antisense composition and method |
May, 2021
(2 years ago) | |
| US10227590 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(1 year, 1 month from now) | |
| US10421966 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(1 year, 1 month from now) | |
| US10968450 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(1 year, 1 month from now) | |
| US9024007 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(1 year, 1 month from now) | |
| US9994851 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(1 year, 1 month from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10533174 | SAREPTA THERAPS INC | Splice-region antisense composition and method |
May, 2021
(2 years ago) | |
| US10266827 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(1 year, 1 month from now) | |
| USRE47691 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(1 year, 1 month from now) | |
| US10995337 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(1 year, 1 month from now) | |
Vyondys 53 is owned by Sarepta Theraps Inc.
Vyondys 53 contains Golodirsen.
Vyondys 53 has a total of 10 drug patents out of which 2 drug patents have expired.
Expired drug patents of Vyondys 53 are:
- US10533174
- US9416361
Vyondys 53 was authorised for market use on 12 December, 2019.
Vyondys 53 is available in solution;intravenous dosage forms.
Vyondys 53 can be used as treatment of duchenne muscular dystrophy (dmd) in patients having a confirmed mutation of the dmd gene that is amenable to exon 53 skipping.
Drug patent challenges can be filed against Vyondys 53 from 13 December, 2023.
The generics of Vyondys 53 are possible to be released after 12 December, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-280) | Dec 12, 2026 |
| New Chemical Entity Exclusivity(NCE) | Dec 12, 2024 |
Drugs and Companies using GOLODIRSEN ingredient
NCE-1 date: 13 December, 2023
Market Authorisation Date: 12 December, 2019
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients having a confirmed mutation of the dmd gene that is amenable to exon 53 skipping
Dosage: SOLUTION;INTRAVENOUS
VYONDYS 53 family patents
